Patient-driven drug development goes prime time
Patient groups shaping R&D through recruiting, funding, forming sponsors
Is more investigator training on the horizon?
Critics see ample evidence to insist on better PI training
Alexion describes itself as “a global biopharmaceutical company that combines groundbreaking science with a steadfast commitment to meeting the needs of patients living with severe, life-threatening and often ultra-rare diseases.”